AccScience Publishing / EJMO / Online First / DOI: 10.36922/EJMO026370506
Cite this article
1
Download
3
Views
Related Info Links
More by Authors Links
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
ORIGINAL RESEARCH ARTICLE

Chemical characterization and hypothesis‑generating network pharmacology analysis of Shenfu Qiangxin pill

Haiyun Zhu1* ,  Yingdong Wu2
Show Less
1 Department of Cardiology, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin , China
2 Graduate School, Tianjin University of Traditional Chinese Medicine, Tianjin , China
Received: 13 September 2026 | Revised: 24 October 2026 | Accepted: 26 October 2026 | Published online: 19 November 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Introduction: Heart failure represents a heavy global clinical medical burden with unsatisfactory long term outcomes under conventional therapeutic regimens. Traditional Chinese medicine exerts beneficial effects for chronic heart failure management via multi-component and multi-target modes of action. Shenfu Qiangxin pill (SFQXP) is a clinically effective herbal formula for chronic heart failure treatment, yet its systematic chemical profiling and underlying molecular mechanisms remain poorly characterized.

Objective: To characterize the chemical constituents of SFQXP and generate testable hypotheses for heart failure-relevant mechanisms using ultra-high-performance liquid chromatography quadrupole orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap-HRMS), network pharmacology, and molecular docking.

Methods: In vitro extracts and rat medicated serum were analyzed using UHPLC-Q-Orbitrap HRMS. Constituents were tentatively annotated against TCM Pro 2.0 and an in-house compound library. Active compounds were screened via SwissADME. Drug-elated and heart failure-associated targets were retrieved from SwissTargetPrediction, GeneCards, and OMIM. Intersection targets were subjected to protein–protein interaction network construction, core-target filtering, and Gene Ontology/Kyoto Encyclopedia of Genes and Genomes enrichment analyses. AutoDock Vina 1.1.2 was used to evaluate molecular docking between sanggenol A and peroxisome proliferator-activated receptor gamma (PPARG).

Results: A total of 232 non-redundant constituents (186 in vitro, 151 serum-derived; 105 shared) were annotated at MSI Level 2 without authentic reference standards. Thirty-five bioactive candidates and 125 overlapping drug-disease targets were obtained, and 33 core targets were screened. Enrichment analyses highlighted cyclic guanosine monophosphate-protein kinase G, cyclic adenosine monophosphate, and calcium signaling pathways associated with ventricular remodeling. Sanggenol A exhibited favorable in silico predicted binding affinity (−8.3 kcal/mol) to PPARG.

Conclusion: This study profiles SFQXP chemical components and puts forward computational mechanistic hypotheses. Anti-heart failure bioactivity has not been experimentally validated; further cellular and animal‑model experiments are required for verification.

Keywords
Shenfu Qiangxin Pill
Heart failure
Ultra-high-performance liquid chromatography quadrupole orbitrap high-resolution mass spectrometry
Network pharmacology
Molecular docking
Ventricular remodeling
Funding
This work was supported by the Key Scientific Research Project in Traditional Chinese Medicine of Tianjin (Grant No. 2024015) and the Traditional Chinese Medicine and Integrated Chinese Western Medicine Scientific Research Project of Tianjin Health Commission (Grant No.2025083).
Conflict of interest
The authors declare that there are no conflicts of interest.
References
  1. Chinese Society of Cardiology, Chinese Medical Association; Chinese College of Cardiovascular Physician; Chinese Heart Failure Association of Chinese Medical Doctor Association; Editorial Board of Chinese Journal of Cardiology. Zhongguo xinli shuaijie zhenduan he zhiliao zhinan 2024 [2024 Chinese guidelines for the diagnosis and treatment of heart failure]. Chin J Cardiol. 2024;52(3):235-275. [In Chinese]. doi: 10.3760/cma.j.cn112148-20231101-00405
  2. Aşkin L, Tanriverdi O. The benefits of sacubitril-valsartan in low ejection fraction heart failure. Abant Med J. 2022;11(3):336-337. doi: 10.47493/abantmedj.1182158
  3. Sun Y. Ma Lianzhen yi Shenfu Qiangxin Wan bianzhi manxing xinshuai jingyan [Professor Ma Lianzhen's experience in differentiating and treating chronic heart failure with Shenfu Qiangxin Pill]. Chin J Basic Med Tradit Chin Med. 2012;18(7):745-746. [In Chinese]. doi: 10.19945/j.cnki.issn.1006-3250.2012.07.023
  4. Yuan H, Zhang DW, Ma XH. Shenfu Qiangxin Wan zhiliao xinli shuaijie youxiaoxing ji anquanxing de Meta fenxi [Efficacy and safety of Shenfu Qiangxin Pill for heart failure: a meta-analysis]. Chin J Integr Med Cardio Cerebrovasc Dis. 2021;19(16):2693-2700. [In Chinese]. doi: 10.12102/j.issn.1672-1349.2021.16.003
  5. Wei YQ, Liu Y, Meng ZR, et al. Shenfu Qiangxin Wan lianhe changgui liaofa zhiliao manxing xinli shuaijie de Meta fenxi [Efficacy and safety of Shenfu Qiangxin Pill combined with conventional therapy for chronic heart failure: a meta-analysis]. China Pharmacy. 2021;32(6):736-742. [In Chinese]. doi: 10.6039/j.issn.1001-0408.2021.06.16
  6. Ma ZY. Shenfu Qiangxin Wan duibi leimipuli zhiliao manxing chongxuexing xinlishuaijie de linchuang liaoxiao [Clinical efficacy of Shenfu Qiangxin Pill vs ramipril in chronic congestive heart failure]. Pract Clin J Integr Tradit West Med. 2023;23(14):41-43. [In Chinese]
  7. Zhang X, Jin Q, Zhuo XM. Shakubaqu xieshatan lianhe Shenfu Qiangxin Wan zhiliao manxing xinli shuaijie de linchuang liaoxiao [Clinical efficacy of sacubitril valsartan combined with Shenfu Qiangxin Pill in chronic heart failure]. Contemp Med. 2021;27(29):127-128. [In Chinese]
  8. Xiong S, Zhao YL, Han S. Shenfu Qiangxin Wan fuzhi manxing xinli shuaijie linchuang guancha [Clinical observation of Shenfu Qiangxin Pill in adjuvant treatment of chronic heart failure]. J Pract Tradit Chin Med. 2024;40(7):1299-1301. [In Chinese]
  9. Yang Y, Yao CL, Guo DA. Insight into chemical basis of traditional Chinese medicine based on liquid chromatography mass spectrometry. Acta Pharm Sin B. 2021;11(6):1469-1492. doi: 10.1016/j.apsb.2021.02.017
  10. Xia Q, Liu M, Li H, et al. Network pharmacology strategy to investigate the pharmacological mechanism of HuangQiXiXin decoction on cough variant asthma. Evid Based Complement Alternat Med. 2020;2020(1):3829092. doi: 10.1155/2020/3829092
  11. Kanehisa M, Goto S. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 2000;28(1):27-30. doi: 10.1093/nar/28.1.27
  12. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455-461. doi: 10.1002/jcc.21334
  13. Hsin KY, Ghosh S, Kitano H. Combining machine learning systems and multiple docking simulation packages to improve docking prediction reliability for network pharmacology. PLoS One. 2013;8(12):e83922. doi: 10.1371/journal.pone.0083922
  14. Xu H, Wang W, Li X, et al. Botany, traditional use, phytochemistry, pharmacology and clinical applications of rhubarb (Rhei Radix et Rhizome): a systematic review. Am J Chin Med. 2024;52(7):1925-1967. doi: 10.1142/S0192415X24500757
  15. Wu Z, Qian J, Feng C, et al. A review of Aconiti Lateralis Radix Praeparata (Fuzi) for kidney disease: phytochemistry, toxicology, herbal processing, and pharmacology. Front Pharmacol. 2024;15:1427333. doi: 10.3389/fphar.2024.1427333
  16. Li Y, Wang H, Zhang Y. Exploring the therapeutic and antitumor properties of morusin: a review of recent advances. Front Mol Biosci. 2023;10:1168298. doi: 10.3389/fmolb.2023.1168298
  17. Evans LW, Ferguson BS, McKinsey TA. Emodin and emodin-rich rhubarb inhibits histone deacetylase (HDAC) activity and cardiac myocyte hypertrophy. J Nutr Biochem. 2020;79:108339. doi: 10.1016/j.jnutbio.2019.108339
  18. Wang Z, Li Y, Zhang L. Unlocking ginsenosides' therapeutic power with polymer-based delivery systems: current applications and future perspectives. Front Pharmacol. 2025;16:1629803. doi: 10.3389/fphar.2025.1629803
  19. Li Y, Jiang JG. Health functions and structure-activity relationships of natural anthraquinones from plants. Food Funct. 2018;9(12):6063-6080. doi: 10.1039/C8FO01569D
Share
Back to top
Eurasian Journal of Medicine and Oncology, Electronic ISSN: 2587-196X Print ISSN: 2587-2400, Published by AccScience Publishing